‘Disney’s Robert Iger Hints at Raising Streaming Prices’ -The Wall Street Journal

https://www.wsj.com/articles/disney-ceo-iger-need-to-figure-out-disney-pricing-strategy-aa470a0a?mod=e2tw

byMichael Horton

March 9, 2023

1 minute read

https://www.wsj.com/articles/disney-ceo-iger-need-to-figure-out-disney-pricing-strategy-aa470a0a?mod=e2tw

Origin Bancorp Q4 EPS $0.55 Misses $0.58 Estimate

By Benzinga Newsdesk

January 22, 5:17 PM

Origin Bancorp (NASDAQ:OBNK) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.58…

OBNK

TransUnion Q2 Adj. EPS $0.98 Beats $0.97 Estimate, Sales $948.00M Miss $964.43M Estimate

By Bill Haddad

July 26, 6:18 AM

TransUnion (NYSE:TRU) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.97 by 1.03 percent. This is a 2.08 percent increase over earnings of $0.96 per share from the same

TRU

FTS International Q2 EPS $(0.19) Misses $(0.12) Estimate, Sales $99.80M Beat $77.10M Estimate

By Benzinga Newsdesk

August 5, 6:10 PM

FTS International (AMEX:FTSI) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 97.99 percent increase over losses of $(9.43) per share from

FTSI

News

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

By Benzinga Newsdesk

August 12, 7:08 AM

AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced

AZRX

‘Disney’s Robert Iger Hints at Raising Streaming Prices’ -The Wall Street Journal

Related Posts

Origin Bancorp Q4 EPS $0.55 Misses $0.58 Estimate

TransUnion Q2 Adj. EPS $0.98 Beats $0.97 Estimate, Sales $948.00M Miss $964.43M Estimate

FTS International Q2 EPS $(0.19) Misses $(0.12) Estimate, Sales $99.80M Beat $77.10M Estimate

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections